Key result
Recombinant human GH is linked to decreased PAI-1 and t-PA levels in deficient adults.
Why the study?
Growth hormone deficiency in adults is associated with premature atherosclerosis and altered fibrinolytic factors, but the effects of long-term GH treatment on coagulation and fibrinolysis are not fully understood.
Does recombinant human growth hormone improve coagulation and fibrinolysis markers in adults with growth hormone deficiency?
Population
17 adult-onset GHD patients receiving conventional hormone replacement therapy
Comparison
Before and during two years of recombinant human GH treatment
Design
Observational cohort study
Follow-up
Two years
Authors
Loading...
May improve fibrinolysis in GHD adults; hypothesis-generating for CV risk reduction.
Observational (n=17)
Does recombinant human growth hormone improve coagulation and fibrinolysis markers in adults with growth hormone deficiency?
p-value: p=< 0.05
Long-term growth hormone treatment in adults with growth hormone deficiency decreases PAI-1 and t-PA antigen levels, suggesting a potential role in regulating fibrinolysis and modifying cardiovascular risk.
Landin‐Wilhelmsen et al. (1996) conducted an observational in Adult-onset growth hormone deficiency (GHD) (n=17). Recombinant human growth hormone (GH) was evaluated on PAI-1 activity, PAI-1 antigen and tissue plasminogen activator (t-PA) antigen levels (p=< 0.05). Two years of recombinant human GH treatment in adults with growth hormone deficiency significantly decreased PAI-1 activity, PAI-1 antigen, and t-PA antigen levels (p < 0.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: